Previous close | 68.40 |
Open | 69.08 |
Bid | 69.34 x 600 |
Ask | 69.40 x 600 |
Day's range | 68.05 - 69.79 |
52-week range | 51.79 - 89.91 |
Volume | |
Avg. volume | 1,087,663 |
Market cap | 10.912B |
Beta (5Y monthly) | 1.22 |
PE ratio (TTM) | 49.94 |
EPS (TTM) | 1.39 |
Earnings date | 01 May 2024 - 06 May 2024 |
Forward dividend & yield | 0.32 (0.46%) |
Ex-dividend date | 09 Feb 2024 |
1y target est | 80.42 |
Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX® qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR.
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 9:45 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.